S'abonner

Postpartum long-acting reversible contraceptive use among active-duty, female US Army soldiers - 26/09/23

Doi : 10.1016/j.ajog.2023.07.023 
Ella F. Eastin, BS a, D. Alan Nelson, MPAS, PhD b, Jonathan G. Shaw, MD, MS b, c, Kate A. Shaw, MD, MS c, Lianne M. Kurina, PhD b,
a Stanford University School of Medicine, Stanford, CA 
b Division of Primary Care and Population Health, Department of Medicine, Stanford University School of Medicine, Stanford, CA 
c Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 

Corresponding author: Lianne M. Kurina, PhD.

Abstract

Background

Postpartum use of long-acting reversible contraception has been found to be effective at increasing interpregnancy intervals, reducing unintended pregnancies, and optimizing health outcomes for mothers and babies. Among female active-duty military service members, reproductive planning may be particularly important, yet little is known about postpartum long-acting reversible contraceptive use among active-duty soldiers.

Objective

This study aimed to (1) quantify postpartum uptake of long-acting reversible contraception among active-duty female US Army soldiers and (2) identify demographic and military-specific characteristics associated with use.

Study Design

This retrospective cohort study used longitudinal data of all digitally recorded health encounters for active-duty US Army soldiers from 2014 to 2017. The servicewomen included in our analysis were aged 18 to 44 years with at least one delivery and a minimum of 4 months of total observed time postdelivery within the study period. We defined postpartum long-acting reversible contraception use as initiation of use within the delivery month or in the 3 calendar months following delivery and identified likely immediate postpartum initiation via the proxy of placement recorded during the same month as delivery. We then evaluated predictors of postpartum long-acting reversible contraception use with multivariable logistic regression.

Results

The inclusion criteria were met by 15,843 soldiers. Of those, 3162 (19.96%) initiated the use of long-acting reversible contraception in the month of or within the 3 months following delivery. Fewer than 5% of these women used immediate postpartum long-acting reversible contraception. Among women who initiated postpartum long-acting reversible contraceptive use, 1803 (57.0%) received an intrauterine device, 1328 (42.0%) received an etonogestrel implant, and 31 received both (0.98%). Soldiers of younger age, self-reported White race, and those who were married or previously married were more likely to initiate long-acting reversible contraception in the postpartum period. Race-stratified analyses showed that self-reported White women had the highest use rates overall. When compared with these women, the adjusted odds of postpartum use among self-reported Black and Asian or Pacific Islander women were 18% and 30% lower, respectively (both P<.001). There was also a trend of decreasing postpartum use with increasing age within each race group. Differences observed between age groups and race identities could partially be attributed to differential use of permanent contraception (sterilization), which was found to be significantly more prevalent among both women aged 30 years or older and among women who identified as Black.

Conclusion

Among active-duty US Army servicewomen, 1 in 5 used postpartum long-acting reversible contraception, and fewer than 5% of these women used an immediate postpartum method. Within this population with universal healthcare coverage, we observed relatively low rates of use and significant differences in the uptake of effective postpartum long-acting contraceptive methods across self-reported race categories.

Le texte complet de cet article est disponible en PDF.

Key words : contraception, contraceptive implant, intrauterine device, long-acting reversible contraception, military, postpartum, universal healthcare


Plan


 The authors report no conflict of interest.
 Cite this article as: Eastin EF, Nelson DA, Shaw JG, et al. Postpartum long-acting reversible contraceptive use among active-duty, female US Army soldiers. Am J Obstet Gynecol 2023;229:432.e1-12.


© 2023  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 229 - N° 4

P. 432.e1-432.e12 - octobre 2023 Retour au numéro
Article précédent Article précédent
  • Proximity of percutaneous tibial nerve stimulation needle insertion to surrounding anatomic structures: a cadaveric study
  • Jenna M. Warehime, Jeremy T. Gaskins, Ankita S. Gupta, Eyas M. Hattab, Rehan T. Feroz, Rodger W. Rothenberger, Stacy M. Lenger, Sean L. Francis, Nicole R. Herring
| Article suivant Article suivant
  • Cell-free DNA screening for trisomy 21 in twin pregnancy: a large multicenter cohort study
  • Lorraine Dugoff, Nathanael C. Koelper, Stephen T. Chasen, Melissa L. Russo, Ashley S. Roman, Meghana A. Limaye, Angela C. Ranzini, Caitlin M. Clifford, Joseph R. Biggio, Akila Subramaniam, Angela Seasely, Avinash S. Patil, Samantha Weed, Jessica M. Page, Sara Nicholas, Jay Idler, Rashmi R. Rao, Amber Crowder, Raj Shree, Graham McLennan, Bryann Bromley

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.